SELLAS Life Sciences Group, Inc. (SLS)
Largest Insider Buys in Sector
SLS Stock Price History Chart
SLS Stock Performance
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal …
Insider Activity of SELLAS Life Sciences Group, Inc.
Over the last 12 months, insiders at SELLAS Life Sciences Group, Inc. have bought $0 and sold $0 worth of SELLAS Life Sciences Group, Inc. stock.
On average, over the past 5 years, insiders at SELLAS Life Sciences Group, Inc. have bought $0 and sold $22,757 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $98,742 was made by Nisi Rudolph (director) on 2014‑02‑07.
List of Insider Buy and Sell Transactions, SELLAS Life Sciences Group, Inc.
| 2022-12-05 | Sale | President and CEO | 6,494 0.0347% | $2.61 | $16,938 | -37.30% | ||
| 2022-12-05 | Sale | EVP, Gen. Counsel, Corp. Sec. | 2,153 0.0114% | $2.59 | $5,576 | -37.30% | ||
| 2022-12-05 | Sale | Senior VP, Finance & CAO | 1,159 0.0061% | $2.59 | $3,002 | -37.30% | ||
| 2021-12-02 | Sale | President and CEO | 2,120 0.0133% | $6.25 | $13,252 | -51.09% | ||
| 2021-12-02 | Sale | EVP, Gen. Counsel, Corp. Sec. | 847 0.0053% | $6.25 | $5,298 | -51.09% | ||
| 2021-12-02 | Sale | VP, Finance & Corp Controller | 231 0.0014% | $6.27 | $1,448 | -51.09% | ||
| 2018-12-31 | Sale | President and CEO | 23,277 0.1061% | $1.25 | $29,189 | -86.59% | ||
| 2017-06-20 | Sale | director | 500 0.0013% | $0.55 | $273 | -50.00% | ||
| 2017-02-08 | Sale | 10 percent owner | 2.36M 9.0582% | $0.84 | $1.99M | -50.00% | ||
| 2014-02-12 | Sale | director | 187,500 0.1611% | $4.33 | $812,438 | -48.39% | ||
| 2014-02-07 | director | 20,000 0.0172% | $4.94 | $98,742 | -53.96% | |||
| 2014-02-03 | Sale | director | 300,000 0.2555% | $4.18 | $1.25M | -45.97% | ||
| 2014-01-30 | Sale | EVP & Chief Operating Officer | 100,000 0.0885% | $5.57 | $556,500 | -57.67% | ||
| 2014-01-30 | Sale | director | 250,000 0.2151% | $5.41 | $1.35M | -57.67% | ||
| 2014-01-30 | Sale | director | 75,000 0.0666% | $5.58 | $418,755 | -57.67% | ||
| 2014-01-29 | Sale | director | 250,000 0.2151% | $5.28 | $1.32M | -56.63% | ||
| 2014-01-23 | Sale | director | 150,000 0.1251% | $5.92 | $888,540 | -62.36% | ||
| 2014-01-22 | Sale | director | 250,000 0.2176% | $6.13 | $1.53M | -61.96% | ||
| 2014-01-17 | Sale | director | 200,000 0.1702% | $6.92 | $1.39M | -66.71% | ||
| 2014-01-17 | Sale | director | 200,000 0.1721% | $7.00 | $1.4M | -66.71% |
Institutional Investor Ownership
| Anson Funds Management Lp | $4.88M | 8.37 | 4.83M | New | +$4.88M | 0.31 | |
| The Vanguard Group | $1.53M | 2.62 | 1.51M | +31.89% | +$369,570.03 | <0.0001 | |
| BlackRock | $281,000.00 | 0.48 | 278,218 | -0.57% | -$1,601.86 | <0.0001 | |
| Geode Capital Management | $275,867.00 | 0.47 | 273,063 | +11.18% | +$27,741.98 | <0.0001 | |
| Opus Capital Group Llc | $203,000.00 | 0.35 | 200,600 | +48.59% | +$66,384.85 | 0.03 |